Is intermittent antiretroviral therapy a satisfactory strategy for the management of patients living with HIV?
Saved in:
| Title: | Is intermittent antiretroviral therapy a satisfactory strategy for the management of patients living with HIV? |
|---|---|
| Authors: | Roland, Thomas1,2, Yombi, Jean C.2 Jean.yombi@uclouvain.be |
| Source: | AIDS Reviews. Jul-Sep2021, Vol. 23 Issue 3, p117-125. 9p. |
| Subjects: | ANTIRETROVIRAL agents, NON-nucleoside reverse transcriptase inhibitors, DRUG efficacy, INTEGRASE inhibitors, QUALITY of life |
| Abstract: | Many innovations, such as long-acting agents, new delivery modalities (injectable and nanoparticles), and novel paradigms (immunotherapy or dual therapy), have been introduced to facilitate the administration of antiretroviral treatment (ART) to patients infected with HIV and improve their adherence and quality of life without altering the drugs' effectiveness. Studies have investigated the use of intermittent treatment, especially weekends-off ART in HIV-suppressed patients. In this review, we analyzed data concerning intermittent ART to help determine if this strategy is reasonable for the management of patients living with HIV. The results of early studies, in 2007-2015, were encouraging, but the studies were flawed because of the small number of patients included, the absence of a control arm, and random designs with variable patterns of ART administration. From 2016, studies have included more patients, and some are prospective, randomized controlled studies. While non-nucleoside reverse transcriptase inhibitors have been most studied, treatment with integrase inhibitors also has been reported, with the findings that viral resistance did not appear when treatment failed with dolutegravir but not with raltegravir. The most recent study, QUATUOR, found that a 4-day on, 3-day off pattern was non-inferior to the continuous pattern (7 days on). Better-quality studies with long-term follow-up (96 weeks or more) are needed to determine the validity of intermittent treatment and the optimal regimens and monitoring to be used in the management of virologically suppressed patients living with HIV. [ABSTRACT FROM AUTHOR] |
| Copyright of AIDS Reviews is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 152985201 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Is intermittent antiretroviral therapy a satisfactory strategy for the management of patients living with HIV? – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Roland%2C+Thomas%22">Roland, Thomas</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Yombi%2C+Jean+C%2E%22">Yombi, Jean C.</searchLink><relatesTo>2</relatesTo><i> Jean.yombi@uclouvain.be</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22AIDS+Reviews%22">AIDS Reviews</searchLink>. Jul-Sep2021, Vol. 23 Issue 3, p117-125. 9p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22ANTIRETROVIRAL+agents%22">ANTIRETROVIRAL agents</searchLink><br /><searchLink fieldCode="DE" term="%22NON-nucleoside+reverse+transcriptase+inhibitors%22">NON-nucleoside reverse transcriptase inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22DRUG+efficacy%22">DRUG efficacy</searchLink><br /><searchLink fieldCode="DE" term="%22INTEGRASE+inhibitors%22">INTEGRASE inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22QUALITY+of+life%22">QUALITY of life</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Many innovations, such as long-acting agents, new delivery modalities (injectable and nanoparticles), and novel paradigms (immunotherapy or dual therapy), have been introduced to facilitate the administration of antiretroviral treatment (ART) to patients infected with HIV and improve their adherence and quality of life without altering the drugs' effectiveness. Studies have investigated the use of intermittent treatment, especially weekends-off ART in HIV-suppressed patients. In this review, we analyzed data concerning intermittent ART to help determine if this strategy is reasonable for the management of patients living with HIV. The results of early studies, in 2007-2015, were encouraging, but the studies were flawed because of the small number of patients included, the absence of a control arm, and random designs with variable patterns of ART administration. From 2016, studies have included more patients, and some are prospective, randomized controlled studies. While non-nucleoside reverse transcriptase inhibitors have been most studied, treatment with integrase inhibitors also has been reported, with the findings that viral resistance did not appear when treatment failed with dolutegravir but not with raltegravir. The most recent study, QUATUOR, found that a 4-day on, 3-day off pattern was non-inferior to the continuous pattern (7 days on). Better-quality studies with long-term follow-up (96 weeks or more) are needed to determine the validity of intermittent treatment and the optimal regimens and monitoring to be used in the management of virologically suppressed patients living with HIV. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of AIDS Reviews is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=152985201 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.24875/AIDSRev.20000108 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 9 StartPage: 117 Subjects: – SubjectFull: ANTIRETROVIRAL agents Type: general – SubjectFull: NON-nucleoside reverse transcriptase inhibitors Type: general – SubjectFull: DRUG efficacy Type: general – SubjectFull: INTEGRASE inhibitors Type: general – SubjectFull: QUALITY of life Type: general Titles: – TitleFull: Is intermittent antiretroviral therapy a satisfactory strategy for the management of patients living with HIV? Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Roland, Thomas – PersonEntity: Name: NameFull: Yombi, Jean C. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 07 Text: Jul-Sep2021 Type: published Y: 2021 Identifiers: – Type: issn-print Value: 11396121 Numbering: – Type: volume Value: 23 – Type: issue Value: 3 Titles: – TitleFull: AIDS Reviews Type: main |
| ResultId | 1 |
